In this panel discussion moderated by Project Farma, experts from Spark, Cellares and Baseline Controls will explore:
Adam Barlow is principal and founder of Baseline Controls Inc. He founded Baseline Controls Inc. in 2010 and currently leads a team of project support professionals. Baseline Controls Inc. specializes in providing its project-centric clients with project management consulting services including strategic and tactical planning, project control services, program management and project execution support. Baseline Controls Inc. professionals seamlessly integrate with clients and use a cost-effective planning approach to deliver programs and projects on time and under budget.
Antinea is the Vice President of Technical Operations at Cellares. She brings over a decade of experience in the Life Sciences industry, having held senior leadership responsibilities in Cell Manufacturing, Technical Operations, MSAT, Supply Chain, Engineering, and Program Management.
Prior to joining Cellares, Antinea oversaw the design, build, and deployment of Synthego's High-Throughput Genome Engineering Technology, a cell-line agnostic platform accelerating researchers' CRISPR-mediated target identification and validation initiatives. She led the commercial launch of CRISPR-edited iPSCs and Engineered Cell Libraries to upend mainstream therapeutic development approaches, enabling researchers to gain valuable diversity, toxicity, and efficacy insights in-situ, de-risking costly therapeutic endeavors far ahead of traditional patient trials. In partnership with the NIH, she led the generation of isogenic-induced pluripotent stem cell (iPSC) lines to establish a national repository to characterize how individual mutations impact cellular pathways and contribute to Alzheimer’s and other neurological indications.
At Novartis, Antinea drove readiness and successful completion of FDA pre-approval inspections (PAI). Antinea holds a Bachelor of Science in Microbial Biology from the University of California, Berkeley and has made it her mission to understand, optimize, and accelerate access to curative therapeutic modalities reinforced through years of innovative, customer-centric genomic advancements across all stages of the drug development process.
Steve is a global biopharmaceutical executive with extensive experience leading large organizations with up to 4,000 personnel in the biopharmaceutical and nuclear industries. Steve spent 26 years in the United States Navy as a nuclear submarine officer where he held several key leadership positions including Commanding Officer of the USS SALT LAKE CITY (SSN 716) as well as Commodore of Submarine Squadron ONE in Pearl Harbor, Hawaii. Steve retired from the Navy as a Captain in 2009.
After retiring from the Navy, Steve spent four years in the civilian nuclear industry working for Areva and then Westinghouse as a project director for large multi-billion dollar new nuclear facilities. In 2014, Steve transitioned to the pharmaceutical industry. He first joined Shire Pharmaceuticals as a project director and site lead where he successfully delivered a new $2B manufacturing facility. Steve spent 3 years as the Head of Capital Programs for Shire where he was accountable for developing and implementing capital management programs and services with direct oversight of the $1B annual capital budget. Steve joined the Spark team in April 2020 as the Head of Real Estate, Corporate Facilities and Capital Programs where he is responsible for leading the evolution of Spark’s expanding corporate facilities portfolio and long term facilities strategy.
Steve is originally from Longmeadow, Massachusetts. He received a B.S. in Ocean Engineering from the United States Naval Academy. He currently resides in Philadelphia, Pennsylvania with his wife, Robin. They have 3 grown children.
Chad Salisbury joined Project Farma in October 2022 as Senior Vice President. Chad has over 20 years of experience encompassing gene therapy, vaccines, sterile injectables and small molecules, including the delivery of ~$2B USD of greenfield cGMP manufacturing facilities. Chad has held increasingly responsible management positions in manufacturing, quality, engineering and supply chain.
Chad was most recently VP, Manufacturing at Affinia Therapeutics, a company singularly focused on using innovations in gene therapy to lead the fight against devastating rare and prevalent diseases. Prior to Affinia, Chad held progressive roles at CSL Seqirus, Novartis and Eli Lilly in both the US and Europe.
Chad holds an MBA from Purdue University, an MEM from Duke University and a B.A. from Alfred University.